DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cryopyrin-associated periodic syndrome", "Cryopyrin associated periodic fever syndrome", "Familial cold autoinflammatory syndrome", "FCAS", "Mucke-Wells syndrome", "MWS", "Chronic infantile neurologic cutaneous, and articular syndrome", "CINCA syndrome", "Neonatal onset multisystem inflammatory disease", "NOMID"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACZ885; ACZ885 drug substance; ATI-450; Anakinra; Anti-interleukin-1B monoclonal antibody; C-028380; CANAKINUMAB; Canakinumab; Canakinumab (ACZ885); Canakinumab (WHO approval pending); Canakinumab (company code: ACZ885D); ILARIS; IZD174; IZD334; Ilaris; Inzomelid; Kineret; Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class; Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class; Rilonacept; Rilonacept 160 mg; Tranilast; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00069329 (ClinicalTrials.gov)	September 2003	22/9/2003	Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease	A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease	Nervous System Malformations;Arthropathy, Neurogenic;Urticaria;Papilledema	Drug: anakinra	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Terminated	N/A	N/A	All	43	Phase 1;Phase 2	United States
2	EUCTR2013-000300-42-Outside-EU/EEA (EUCTR)		18/01/2013	A long-term study with the IL-1 receptor blocker anakinra/kineret® in patients with neonatal onset multisystem inflammatory disease (NOMID/CINCA syndrome)	A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)	neonatal onset multisystem inflammatory disease (NOMID/CINCA);Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Kineret	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	NA			Female: yes Male: yes	50		United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00069329
(ClinicalTrials.gov)

September 2003

22/9/2003

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease

Nervous System Malformations;Arthropathy, Neurogenic;Urticaria;Papilledema

Drug: anakinra

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NULL

Terminated

N/A

All

Phase 1;Phase 2

United States

EUCTR2013-000300-42-Outside-EU/EEA
(EUCTR)

18/01/2013

A long-term study with the IL-1 receptor blocker anakinra/kineret® in patients with neonatal onset multisystem inflammatory disease (NOMID/CINCA syndrome)

A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)

neonatal onset multisystem inflammatory disease (NOMID/CINCA);Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: Kineret

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NULL

Female: yes
Male: yes

United States